Safety issues in isotretinoin therapy

N. Hanson, Sancy Leachman

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Isotretinoin (Accutane, Roche Laboratories Inc, Nutley, NJ) is an important drug, not only for the treatment of severe acne, but also for other diagnoses and in chemoprevention settings. Because the use of isotretinoin is increasing, it is important for physicians to be aware of the adverse events, toxicities, and management issues related to its use. The most important issue is that of congenital defects, which has resulted in new pregnancy prevention policies and programs implemented by the manufacturer. A relatively new concern is that of depression associated with isotretinoin use, also resulting in new policies placed by the manufacturer and the FDA. The most common adverse effects observed during treatment are mucocutaneous and ocular in nature, but laboratory abnormalities and effects in the nervous, musculoskeletal, gastrointestinal, pulmonary, hematologic, and other systems are also described. Additionally, potential drug interactions, follow-up, and toxicity prevention measures are discussed.

Original languageEnglish (US)
Pages (from-to)166-183
Number of pages18
JournalSeminars in Cutaneous Medicine and Surgery
Volume20
Issue number3
StatePublished - 2001
Externally publishedYes

Fingerprint

Isotretinoin
Safety
Acne Vulgaris
Chemoprevention
Therapeutics
Drug Interactions
Physicians
Pregnancy
Lung
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Dermatology

Cite this

Safety issues in isotretinoin therapy. / Hanson, N.; Leachman, Sancy.

In: Seminars in Cutaneous Medicine and Surgery, Vol. 20, No. 3, 2001, p. 166-183.

Research output: Contribution to journalArticle

@article{851f32f91f944b3aaa83c870714e40e1,
title = "Safety issues in isotretinoin therapy",
abstract = "Isotretinoin (Accutane, Roche Laboratories Inc, Nutley, NJ) is an important drug, not only for the treatment of severe acne, but also for other diagnoses and in chemoprevention settings. Because the use of isotretinoin is increasing, it is important for physicians to be aware of the adverse events, toxicities, and management issues related to its use. The most important issue is that of congenital defects, which has resulted in new pregnancy prevention policies and programs implemented by the manufacturer. A relatively new concern is that of depression associated with isotretinoin use, also resulting in new policies placed by the manufacturer and the FDA. The most common adverse effects observed during treatment are mucocutaneous and ocular in nature, but laboratory abnormalities and effects in the nervous, musculoskeletal, gastrointestinal, pulmonary, hematologic, and other systems are also described. Additionally, potential drug interactions, follow-up, and toxicity prevention measures are discussed.",
author = "N. Hanson and Sancy Leachman",
year = "2001",
language = "English (US)",
volume = "20",
pages = "166--183",
journal = "Seminars in Cutaneous Medicine and Surgery",
issn = "1085-5629",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Safety issues in isotretinoin therapy

AU - Hanson, N.

AU - Leachman, Sancy

PY - 2001

Y1 - 2001

N2 - Isotretinoin (Accutane, Roche Laboratories Inc, Nutley, NJ) is an important drug, not only for the treatment of severe acne, but also for other diagnoses and in chemoprevention settings. Because the use of isotretinoin is increasing, it is important for physicians to be aware of the adverse events, toxicities, and management issues related to its use. The most important issue is that of congenital defects, which has resulted in new pregnancy prevention policies and programs implemented by the manufacturer. A relatively new concern is that of depression associated with isotretinoin use, also resulting in new policies placed by the manufacturer and the FDA. The most common adverse effects observed during treatment are mucocutaneous and ocular in nature, but laboratory abnormalities and effects in the nervous, musculoskeletal, gastrointestinal, pulmonary, hematologic, and other systems are also described. Additionally, potential drug interactions, follow-up, and toxicity prevention measures are discussed.

AB - Isotretinoin (Accutane, Roche Laboratories Inc, Nutley, NJ) is an important drug, not only for the treatment of severe acne, but also for other diagnoses and in chemoprevention settings. Because the use of isotretinoin is increasing, it is important for physicians to be aware of the adverse events, toxicities, and management issues related to its use. The most important issue is that of congenital defects, which has resulted in new pregnancy prevention policies and programs implemented by the manufacturer. A relatively new concern is that of depression associated with isotretinoin use, also resulting in new policies placed by the manufacturer and the FDA. The most common adverse effects observed during treatment are mucocutaneous and ocular in nature, but laboratory abnormalities and effects in the nervous, musculoskeletal, gastrointestinal, pulmonary, hematologic, and other systems are also described. Additionally, potential drug interactions, follow-up, and toxicity prevention measures are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0034806094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034806094&partnerID=8YFLogxK

M3 - Article

C2 - 11594672

AN - SCOPUS:0034806094

VL - 20

SP - 166

EP - 183

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

SN - 1085-5629

IS - 3

ER -